Technical Analysis for ALIM - Alimera Sciences, Inc.

Grade Last Price % Change Price Change
B 10.3 -0.77% -0.08
ALIM closed down 0.77 percent on Friday, June 11, 2021, on 29 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat
Historical ALIM trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Outside Day Range Expansion -0.77%
Overbought Stochastic Strength -0.77%
Overbought Stochastic Strength -0.29%
Stochastic Sell Signal Bearish 2.69%
Overbought Stochastic Strength 2.69%
50 DMA Support Bullish 0.10%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.10%
Multiple of Ten Bullish Other 0.10%
Older End-of-Day Signals for ALIM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Alimera Sciences, Inc. Description

Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company's principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye to a placement site that takes advantage of the eye's natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Medicine Biopharmaceutical Diseases Eye Disease Organ Systems Diabetes Ophthalmic Macular Degeneration Related Macular Degeneration Retina Diabetic Retinopathy Icos Macular Edema Blindness Vein Age Related Macular Degeneration Diabetic Macular Edema Pivotal Fluid Dynamics Glucocorticoids Corticosteroid Pregnanes Alimera Sciences Diketones Fluocinolone Psivida Retinal Vein Occlusion

Is ALIM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 12.21
52 Week Low 3.82
Average Volume 37,319
200-Day Moving Average 7.10
50-Day Moving Average 9.92
20-Day Moving Average 9.89
10-Day Moving Average 10.27
Average True Range 0.43
ADX 11.47
+DI 18.35
-DI 17.89
Chandelier Exit (Long, 3 ATRs) 9.22
Chandelier Exit (Short, 3 ATRs) 9.68
Upper Bollinger Bands 10.99
Lower Bollinger Band 8.78
Percent B (%b) 0.69
BandWidth 22.28
MACD Line 0.17
MACD Signal Line 0.12
MACD Histogram 0.0435
Fundamentals Value
Market Cap 52.86 Million
Num Shares 5.13 Million
EPS 0.30
Price-to-Earnings (P/E) Ratio 33.99
Price-to-Sales 0.43
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.62
Resistance 3 (R3) 10.65 10.57 10.56
Resistance 2 (R2) 10.57 10.49 10.56 10.54
Resistance 1 (R1) 10.44 10.44 10.40 10.41 10.53
Pivot Point 10.36 10.36 10.35 10.35 10.36
Support 1 (S1) 10.23 10.28 10.19 10.20 10.07
Support 2 (S2) 10.15 10.23 10.14 10.06
Support 3 (S3) 10.02 10.15 10.04
Support 4 (S4) 9.99